Search

Your search keyword '"Ph. Gabriel Steg"' showing total 21 results

Search Constraints

Start Over You searched for: Author "Ph. Gabriel Steg" Remove constraint Author: "Ph. Gabriel Steg" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
21 results on '"Ph. Gabriel Steg"'

Search Results

1. Effect of alirocumab on cataracts in patients with acute coronary syndromes

2. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

3. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT

4. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

5. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy

6. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT

7. Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation

9. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG

10. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT

11. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab

14. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

15. Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery

16. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

17. Incidence of Myocardial Infarction Types in Patients Treated With Ticagrelor in the THEMIS Trial

18. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL

19. The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl

20. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction

21. Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX

Catalog

Books, media, physical & digital resources